If you've been following GLP-1 medication access over the past two years, 2026 has brought significant regulatory turbulence. Here's a clear-eyed update on where things actually stand with compounded semaglutide.
Background: Why Compounding Existed
When Ozempic and Wegovy (both semaglutide) faced severe shortages starting in 2022, the FDA added semaglutide to its official drug shortage list. Under federal law, pharmacies can legally compound drugs on the shortage list.
This triggered a boom in compounding pharmacy production of semaglutide — hundreds of telehealth companies offering compounded semaglutide at $150-300/month versus $1,200+ for branded Wegovy. Millions of patients accessed GLP-1 medications who otherwise couldn't afford them.
The FDA's Shortage Removal Decision
In early 2026, the FDA removed semaglutide from the drug shortage list. When a drug comes off the shortage list, the legal basis for compounding largely disappears for most compounders. The FDA issued guidance with enforcement timelines:
- 503B outsourcing facilities: Enforcement after a 90-day wind-down period
- 503A pharmacies: Some continued protections for patient-specific compounds
Novo Nordisk (maker of Ozempic/Wegovy) aggressively lobbied for the removal and has been active in pursuing enforcement actions against compounders.
The Legal Fight Back
Multiple lawsuits were filed — the Outsourcing Facilities Association, individual compounders, and state-level legislation have all pushed back. Courts have issued mixed rulings, and as of early 2026, the situation is genuinely unsettled.
What Does This Mean Practically?
The picture varies by where you get it: - Telehealth companies sourcing from 503B facilities may be more affected - Those sourcing from 503A pharmacies that compound for individual prescriptions have more protection - Some facilities are moving to "personalized" compounding protocols that add B12 or other nutrients
Pricing trends: Compounded semaglutide pricing has been rising as supply has tightened. Some providers have shifted focus to tirzepatide.
Tirzepatide: The Clearer Alternative
As of this writing, tirzepatide remains on the FDA drug shortage list — meaning compounded tirzepatide has a clear legal basis. This is a significant reason why many telehealth providers have shifted emphasis toward tirzepatide protocols.
The clinical data on tirzepatide shows efficacy at least equivalent to and often exceeding semaglutide for weight loss. For many patients, this is actually a favorable development.
How to Protect Your Access
Questions to ask your current provider: 1. What is the compounding pharmacy's classification (503A vs 503B)? 2. How are they navigating the current regulatory environment? 3. Do they offer tirzepatide as an alternative?
Options to consider: - If you're on compounded semaglutide and concerned, assess whether tirzepatide would be appropriate - Check if your insurance newly covers GLP-1s — many plans have expanded coverage - Novo Nordisk's patient assistance programs have expanded for income-eligible patients
The Bottom Line
The situation is in flux, and working with a telehealth provider that actively monitors the regulatory environment — and has access to both semaglutide and tirzepatide formulations — is the most pragmatic approach. We'll continue updating this piece as the regulatory situation develops.
Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
The situation is actively evolving. The FDA removed semaglutide from its drug shortage list in early 2026, triggering efforts to restrict compounding. The legal status varies by pharmacy type — 503A pharmacies retain more protections than 503B facilities. Check with your provider for current status.
What's the difference between 503A and 503B compounding for semaglutide?
503A pharmacies compound for individual patients with a valid prescription. 503B outsourcing facilities produce larger batches for distribution to clinics. After a drug leaves shortage, FDA enforcement typically begins with 503B facilities first.
Is compounded tirzepatide still available?
As of early 2026, tirzepatide remains on the FDA shortage list, meaning compounded tirzepatide remains clearly legal. The situation with semaglutide is more complex.
Get our free Body Composition Guide
Protein protocols, workout structure, sleep optimization, and the supplement stack that actually works.
Get our free Body Composition Guide →
